Ask Warren

Inventage Lab

389470 · KOSDAQ · ₩389470 · 인벤티지랩

₩22,800▼ ₩50 (0.22%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −51.07%
Market cap
₩303B
Enterprise value
₩221B
P/E
—
P/B
3.4×
Dividend yield
0.0%
ROE
−3.6%
Net margin
−127.0%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−77.6% from the high

₩22,550Today: ₩22,750 – ₩24,450₩101,700

Returns

  • 1W−9.2%
  • 1M−6.9%
  • 3M−17.1%
  • 6M−63.4%
  • YTD−72.9%
  • 1Y−51.1%
Volume today
47,253
0.4× the 20-day average
Traded today
₩1.1B
Listed shares
13,307,708
EPS (12 months)
−₩236
Earnings yield −1.0%
SellBuy
AI research · InitiationInventage Lab: Persistent Losses, Cash Cushion and a Share Price Well Below Its 52-Week HighThe data shows a loss-making biotech with very small revenue, a sizeable cash balance and a share price that has fallen sharply from its high but still sits far above the model's per-share estimate.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

31Quiet
  • BuzzQuietBuzz 31 of 100 (50 is a normal day for this stock).
  • MomentumWeak-8.8% over the last month; the price is below its 20-day average.
  • News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

Inventage Lab stock overview

Inventage Lab (인벤티지랩, KRX: 389470) is listed on KOSDAQ, in the Biotech & Pharma sector. Inventiva-style DDS platform company Ivlnet-like Korean firm develops long-acting injectables and drug delivery technologies based on its Laminar-FLUIDigm platform, including IVL-DrugFluidic for long-acting injectables, IVL-GeneFluidic for lipid nanoparticle formulation of genetic medicines, and BioFluidic for protein-based biologics such as antibodies and ADCs. Its shares closed at ₩22,800 on Oct 27, 2026, down 0.22% on the day, giving it a market value of ₩303B.

Key facts

Market cap
₩303B
Sector
Biotech & Pharma
Latest price change
−0.22%
As of
Oct 27, 2026
Main business
Inventiva-style DDS platform company Ivlnet-like Korean firm develops long-acting injectables and drug delivery technologies based on its Laminar-FLUIDigm platform, including IVL-DrugFluidic for long-acting injectables, IVL-GeneFluidic for lipid nanoparticle formulation of genetic medicines, and BioFluidic for protein-based biologics such as antibodies and ADCs.

Quick answers about Inventage Lab

What does Inventage Lab do?
Inventiva-style DDS platform company Ivlnet-like Korean firm develops long-acting injectables and drug delivery technologies based on its Laminar-FLUIDigm platform, including IVL-DrugFluidic for long-acting injectables, IVL-GeneFluidic for lipid nanoparticle formulation of genetic medicines, and BioFluidic for protein-based biologics such as antibodies and ADCs. It partners with domestic and global pharmaceutical companies through licensing and joint development, and offers LNP contract development and manufacturing services and manufacturing systems for mRNA vaccines and gene therapies. Its veterinary product Durahart SR-3 is sold in Korea.
What is the market cap of Inventage Lab?
The market capitalisation of Inventage Lab was ₩303B at the close on Oct 27, 2026.
Who are the largest shareholders of Inventage Lab?
According to the latest official filings, the largest reported holders are Kim Ju-hee (10.49%, as of Jun 16, 2026); Smilegate Investment (4.88%, as of Jan 7, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.78%, as of Jul 31, 2026).
When is the next earnings report from Inventage Lab?
Korean companies rarely announce results dates in advance. Based on when Inventage Lab filed the same report in past years, its next 3q results is expected between Nov 14, 2026 and Dec 1, 2026.
Does the National Pension Service own Inventage Lab?
Yes. The National Pension Service held 0.31% of Inventage Lab shares as of Dec 31, 2025.

Company profile

Inventiva-style DDS platform company Ivlnet-like Korean firm develops long-acting injectables and drug delivery technologies based on its Laminar-FLUIDigm platform, including IVL-DrugFluidic for long-acting injectables, IVL-GeneFluidic for lipid nanoparticle formulation of genetic medicines, and BioFluidic for protein-based biologics such as antibodies and ADCs. It partners with domestic and global pharmaceutical companies through licensing and joint development, and offers LNP contract development and manufacturing services and manufacturing systems for mRNA vaccines and gene therapies. Its veterinary product Durahart SR-3 is sold in Korea.

Written by AI from the company's latest annual report.

Korean name
인벤티지랩
Sector
Biotech & Pharma
Themes
Contract drug manufacturing (CDMO)Obesity drugs
CEO
김주희
Founded
May 2015
Listed
Nov 2022
Listed shares
13,307,708
Fiscal year ends
Month 12
Website
www.inventagelab.com

Similar companies

Recent news

News · Edaily·

Inventygen Lab Receives US Patent Registration for 12-Month Sustained Veterinary Castration Agent, Expanding Commercialization Discussions

Inventage Lab₩22,800▼0.22%
Read the original ↗

Predicted impact: Low· Actual: +0.9% vs sector, volume 0.8× normal (5 trading days)

US patent registration for veterinary castration agent; commercial impact small and vague, no revenue figures given.

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Inventage Lab / 인벤티지랩 / 389470 / KRX:389470

Source: KRX statistical information